Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma Inc. notified the SEC on Form 12b-25 that its Form 10-K for the period ended December 31, 2025 could not be filed on time due to time constraints in compiling, disseminating and reviewing required information. The company states it will file the Form 10-K no later than fifteen days after the original prescribed due date.
The notification was signed by Dr. Steve N. Slilaty, Chief Executive Officer on March 31, 2026. A contact phone number is provided for follow-up.
Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. is informing holders that on February 18, 2026 the majority stockholder approved an amendment authorizing the Board to effect, at its discretion, a reverse stock split of up to 1-for-10. The Board may set any whole-number ratio up to 1-for-10 or abandon the action prior to filing.
The stated purpose is to address Nasdaq Rule requirements, including the minimum $1.00 bid price, and to potentially improve marketability. As of February 18, 2026, there were 4,905,945 shares outstanding; a 1-for-10 split would reduce outstanding shares to 490,595, subject to rounding.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. notified holders that the holder of approximately 96.4% voting power, Dr. Steve N. Slilaty, approved by written consent an amendment to permit a reverse stock split of the common stock by a ratio of up to 1-for-10, with the Board having sole discretion whether to implement the split and to set the exact whole-number ratio up to 1-for-10.
As of February 18, 2026, the company had 4,905,945 shares outstanding; at a 1-for-10 split that figure would become 490,595 shares (fractional shares rounded up). The stated purpose is to address Nasdaq’s $1.00 minimum bid-price requirement; effectiveness requires filing the amendment with the Colorado Secretary of State.
Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.
Sunshine Biopharma Inc. reported the results of its annual stockholder meeting held on December 11, 2025. Stockholders elected five directors — including Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller — to serve until the next annual meeting or until successors are elected and qualified.
Shareholders also ratified the appointment of M&K CPAS, PLLC as the company’s independent registered public accounting firm for 2025. In addition, they approved an amendment to the 2023 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan to 683,000, providing additional equity available for future employee and director compensation awards.
Sunshine Biopharma (SBFM) filed its Q3 2025 10‑Q, highlighting year‑over‑year revenue growth and a smaller quarterly loss. Revenue for the quarter reached $9,417,179, up 11.6% from a year ago, with gross profit of $3,073,540. Operating loss was $1,086,613, and net loss narrowed to $883,820, or $0.19 per share.
For the nine months ended September 30, 2025, revenue was $27,728,750 (up 9.7%). Net loss for the period was $3,834,425, reflecting higher G&A and a $1,616,459 impairment of intangible assets tied to product licenses that could not be commercialized. Cash and equivalents were $9,306,438 as of September 30, 2025.
The company completed an April 2025 registered direct offering, receiving $1,828,596 in net proceeds, and reported additional cash from warrant exercises during the year. Shares outstanding were 4,555,945 as of September 30, 2025, and 4,905,945 as of November 13, 2025. Management aims to reduce cost of goods sold toward 60% to move toward breakeven while continuing to expand Nora Pharma’s Canadian generic portfolio.
Sunshine Biopharma (SBFM) will hold its 2025 virtual annual meeting on December 11, 2025 to vote on three items: elect five directors, ratify M&K CPAS, PLLC as auditor, and amend the 2023 Equity Incentive Plan to increase shares authorized for issuance from 1,661 to 683,000.
The record date is October 17, 2025, with 4,905,945 common shares and 130,000 Series B Preferred outstanding. Each Series B Preferred share carries 1,000 votes, and all Series B shares are held by the CEO, concentrating voting power. The Board recommends voting FOR all proposals.
Auditor history was addressed: following the SEC’s settled order permanently barring BF Borgers from practicing before the SEC, the company dismissed Borgers in 2024, engaged Bush & Associates, and on September 24, 2025 appointed M&K CPAS, PLLC. Executive agreements disclose severance terms, including $14,000,000 for the CEO upon certain terminations. Pay-versus-performance data shows 2024 net loss of $(5,134,116) and a total shareholder return of (99.9%) based on a $1.00 investment benchmark.
Sunshine Biopharma Inc. reported a change in its independent auditor. Effective September 24, 2025, the company dismissed Bush & Associates CPA LLC as its independent registered public accounting firm and engaged M&K CPAS, PLLC as its new auditor. The board of directors and audit committee approved this decision by unanimous consent.
The company states that for the fiscal years ended December 31, 2023 and 2024, and through September 24, 2025, there were no disagreements with Bush & Associates on accounting principles, financial statement disclosure, or audit procedures, and no reportable events under SEC rules. Bush & Associates’ prior audit reports did not contain adverse opinions, disclaimers, or qualifications. Sunshine Biopharma has requested a letter from Bush & Associates to the SEC regarding these disclosures and plans to file it by amendment once received.